Clinical Trial · NCT07316309

CXCR4 PET/CT for Predicting Outcome in Limited-Stage Small Cell Lung Cancer

Overview

This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC). Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker. The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.

Sponsor

Peking University Cancer Hospital & Institute

Contacts

Jie Liu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07316309

Eligibility

Inclusion

Histopathologically confirmed limited-stage small cell lung cancer (T1-4N0-3M0) according to the AJCC TNM 8th edition.
Underwent baseline \[18F\]AlF-NOTA-QHY-04 PET/CT imaging prior to treatment.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Newly diagnosed patients who had not received any prior anticancer treatment.
Presence of measurable disease according to RECIST version 1.1.

Exclusion

Presence of autoimmune diseases or active comorbid infections.
Pregnancy or breastfeeding.